Bartholdson John A.

Chairman Bartholdson sells 113,440 shares (75.6% of holdings) in 3 days for $1,764,532.77 at blended $15.55

Chairman John A. Bartholdson executed 3 separate sales over March 10–12, 2025, totaling 113,440 shares for $1,764,532.77 at a blended average price of $15.55, reducing his stake from 150,000 shares to 36,560 shares. The rapid succession of large sales—selling 75.6% of his pre-transaction holdings in just three days—stands out as a material reduction in insider ownership. The current stock price of $15.22 is now -18.0% from its 52-week high of $18.55 and down -12.7% over the prior 30 days, suggesting the sales occurred as the stock faced downward momentum. Notably, Bartholdson's cross-ticker track record shows 5 prior buys with poor average returns (avg 30d return -21.0%, 90d win rate 0.00%), and his 2 prior same-ticker sales at LINC in late February/early March remain too recent to measure outcomes; the scale and speed of this divestiture in a declining market warrants attention to any accompanying disclosures or material developments.

Chairman Bartholdson sold 275,544 shares for $5.0M at $18.17 blended avg, reducing holdings by 64.8%

Bartholdson executed two separate sales totaling 275,544 shares for $5,006,134.09, reducing his position from 425,544 shares to 150,000 shares—a 64.8% reduction in holdings. The sales occurred on 2025-02-28 at $18.09 and 2025-03-03 at $18.50, near the 52-week high of $18.55. However, the insider's cross-ticker track record across all tickers shows 5 prior buys with an average 90-day return of -14.6% and a 0.00% win rate, indicating a history of poorly-timed entries at this insider's typical buying activity. The current stock price of $17.72 is down 4.5% from the 52-week high and the company trades at a P/E of 55.38 despite posting recent revenue growth of 16.4% and quarterly net income of $4.0M. The magnitude and timing of this concentrated reduction in the chairman's direct ownership warrant examination of whether it reflects a shift in capital allocation priorities or broader confidence levels in the equity position.

Director Bartholdson acquires 105,500 shares across 2 transactions ($8.55 avg) despite poor timing record

John A. Bartholdson, Director of Bioventus Inc., executed 2 separate purchases totaling 105,500 shares for $901,702.35 at $8.55 per share on August 16 and August 19, 2024. His prior trades at BVS show a concerning pattern: 3 prior buys across 2023 all yielded negative 30- and 90-day returns, with a 0% win rate at the 90-day mark. Cross-ticker, his 3 prior open-market buys averaged -32.2% over 30 days and -21.6% over 90 days with a 0.00% win rate. The company remains unprofitable with annual revenue growth of +0.0% and trailing net income of -$23,992,000.00. While the stock has rallied +14.4% over 30 days and +30.2% over 90 days from prior lows, the director's historical execution timing provides no statistical support for forward momentum.